Brandon Capital Partners Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 20
- Investments
- 56
- Portfolio
- 28
- Exits
- 17
Brandon Capital Partners General Information
Description
Founded in 2007, Brandon Capital Partners is a venture capital firm based in Melbourne, Australia. The firm prefers to invest in pharmaceuticals, biotechnology, healthcare devices and supplies, life sciences, digital health, HealthTech, Oncology, and manufacturing sectors in Australia and New Zealand.
Contact Information
Website
www.brandoncapital.com.au
Year Founded
2007
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- Level 9
- 31 Queen Street
- Melbourne, Victoria 3000
- Australia
+61 (03) 0000 0000
Brandon Capital Partners Investments (56)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Q-Sera | 01-Oct-2021 | Later Stage VC | Medical Supplies | Generating Revenue | ||
| 00000 000000000000 | 09-Sep-2021 | 00000 00000 | 000.00 | Managed Care | Generating Revenue | 00000000 0000 |
| 000000 00000000000 | 07-Jul-2021 | 00000 00000 | 0000 | Biotechnology | Out of Business | 000000 0000000000 |
| 000000 000000000 | 22-Jun-2021 | 00000 00000 | 0000 | Drug Discovery | Startup | 0000000 0000000 00.0 |
| 000 00000000000 | 15-Jun-2021 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 00000000000 00000 00.0 |
| 000000 000000 | 27-May-2021 | 0000 00000 | 00.000 | Drug Discovery | Generating Revenue | 00000 00000000 00.0 |
| 00000 00000000000 | 22-Oct-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 00000000000 0000 00.0 |
| 000 00000000000 | 28-Sep-2020 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000000000 00000 00.0 |
| George Health | 10-Mar-2020 | PE Growth/Expansion | 0000 | Drug Discovery | Generating Revenue | |
| Glyscend Therapeutics | 07-Feb-2020 | Later Stage VC | 000.00 | Drug Discovery | Clinical Trials - Phase 1 | 000 000 00 |
Brandon Capital Partners Exits (17)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Amaroq Therapeutics | 06-Jan-2022 | Out of Business | |
| 0000000 0000000 | 16-Dec-2021 | 000 00 00000000 | |
| 000 0000000 | 24-Nov-2021 | 000 | 000.00 |
| 00000000 | 01-Jun-2021 | 000000000 00000000 | |
| 00000000 | 02-Apr-2021 | 000 00 00000000 | |
| 0000 000000000000 | 30-Nov-2020 | 000000000000000000 | 00000 |
| 0000000 000 | 01-Jul-2019 | 000 00 00000000 | |
| 000000000 | 30-Apr-2019 | 000 00 00000000 | |
| Elastagen | 06-Apr-2018 | Merger/Acquisition | 00000 |
| Heart Metabolics | 01-Nov-2017 | Out of Business |
Brandon Capital Partners Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialBrandon Capital Partners Team (30)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Amy Perkin | Chief Financial Officer | Melbourne, Australia | |||
| Christopher Nave Ph.D | Co-Founding Partner & Managing Director | 00 | 0 | 0 | Melbourne, Australia |
| Henry Thompson Ph.D | Co-Founding Partner & Managing Director | 00 | 0 | 0 | Sydney, Australia |
| David Fisher Ph.D | Venture Partner | 0 | 0 | 0 | Sydney, Australia |
| Katharine Giles | Venture Partner | 0 | 0 | 0 | Perth, Australia |
Brandon Capital Partners Co-Investors (45)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| The Medical Research Commercialisation Fund | 15 | 0 | 0 |
|
|
| Stoic Venture Capital | 0 | 0 |
|
|
|
| Uniseed | 0 | 0 |
|
|
|
| CSL | 0 | 0 |
|
|
|
| New Enterprise Associates | 0 | 0 |
|
|